World Journal of Urology

, Volume 21, Issue 5, pp 346–355 | Cite as

Androgen therapy with dehydroepiandrosterone

Topic Paper


The physiological role of dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS) is poorly understood. It depends in a large part on their transformation into testosterone and estradiol. The capacity of DHEA as a neurosteroid, the recent discovery of putative specific DHEA receptors on endothelial and vascular smooth muscle cells, the steady decrease of DHEA production from the 40s on, together with certain human epidemiologic data as well as various beneficial effects of DHA supplementation in rodents have suggested the possibility that this steroid is involved in cognitive and memory, metabolic and vascular, immune and sexual functions and in their aging. However, epidemiologic studies are conflicting, and no well-designed clinical trials have definitely substantiated the role of DHEA in these functions in humans, or the utility and safety of DHEA supplementation. However, beneficial effects seem plausible in women with several conditions according to the results of double-blind placebo-controlled trials: the dose of 30 to 50 mg seems beneficial to the mood, sense of well being and sexual desire and activity of women with adrenal insufficiency. The only long-term trial of supplementation devoted to women over 60 reported significant increases in bone mineral density and, in the 70–79-year-old subgroup, in sexual desire, arousal, activity and satisfaction. The dose of 200 mg also proved to decrease disease activity in systemic lupus erythematosus. Lastly, high DHEA doses have improved mood in various groups of patients of any age and gender with depressive symptoms. The use of DHEA therapy may also be discussed in women of any age when a trial of androgen supplementation seems justified because of the existence of an inhibited sexual desire or a sexual arousal disorder associated with documented androgen deficiency. The rather weak conversion of DHEA into testosterone protects from the risk of overdosing associated with testosterone preparations. However, it must be realized that DHEA is also converted into estradiol, which may be a risk factor for breast or endometrial cancer in postmenopausal women. Unlike women, no consistent beneficial effect has been found for men in the placebo-controlled trials. The present data do not exclude a role of DHEA in other conditions, but this remains to be properly established. This paper includes practical considerations on dosage to be used, contraindications and follow-up.


Dehydroepiandrosterone Androgen replacement therapy Aging Erectile dysfunction 


  1. 1.
    Artl W, Callies F, Van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. New Engl J Med 341:1013–1020PubMedGoogle Scholar
  2. 2.
    Artl W, Haas J, Callies F, et al (1999) Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 84:2170–2176PubMedGoogle Scholar
  3. 3.
    Artl W, Callies F, Koehler I, Van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 86:4686–4692PubMedGoogle Scholar
  4. 4.
    Bachmann GA (2002) The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 77 [Suppl 4]:S72–S76Google Scholar
  5. 5.
    Barnhart KT, Freeman E, Grisso JA et coll (1999) The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 84:3896–3902Google Scholar
  6. 6.
    Barrett-Connor E, Khow KT, Yen SSC (1986) A prospective study of DHEAS, mortality, and cardiovascular disease. New Engl J Med 315:1519–1524PubMedGoogle Scholar
  7. 7.
    Barret-Connor E, Goodman-Gruen D (1995) Dehydroepiandrosterone sulfate does not predict cardiovascular death in post-menopausal women: The Rancho Bernardo Study. Circulation 91:1757–1760PubMedGoogle Scholar
  8. 8.
    Barret-Connor E, Ferrara A (1996) Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab 81:59–64PubMedGoogle Scholar
  9. 9.
    Barret-Connor E, Von Mühlen D, Laughlin GA, Kripke A (1999) Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 47:685–691PubMedGoogle Scholar
  10. 10.
    Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, et al (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEA age study to a sociobiomedical issue. PNAS 97:4279–4284CrossRefPubMedGoogle Scholar
  11. 11.
    Baulieu EE (2001) Neurostéroïdes, leur rôle dans le fonctionnement du cerveau: neurotrophicité, mémoire, vieillissement. Bull Acad Natle Méd 185:349–372Google Scholar
  12. 12.
    Beral V, Banks E, Reeves G (2002) Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 360:942–944CrossRefPubMedGoogle Scholar
  13. 13.
    Berkman LF, Seeman TE, Albert M, Blazer D, Kahn R, Mohs R, et al (1993) High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on Successful Aging. J Clin Epidemiol 46:1129–1140PubMedGoogle Scholar
  14. 14.
    Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE (1996) Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA, 93:13410–13415Google Scholar
  15. 15.
    Bloch M, Schmidt PJ, Danaceau MA, Adam LF, Rubinow DR (1999) Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatr 45:1533–1541PubMedGoogle Scholar
  16. 16.
    Burger H, Hailes J, Nelson J, Menelaus M (1987) Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J (Clin Res Ed) 294:936–937Google Scholar
  17. 17.
    Burger HG (2002) Androgen production in women. Fertil Steril 77 [Suppl 4]:S3–S5Google Scholar
  18. 18.
    Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abraham GE, Buster JE (1995) Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 63:1027–1031PubMedGoogle Scholar
  19. 19.
    Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster JE (1998) Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high density lipoprotein: a 6-month trial. Fertil Steril 70:107–110CrossRefPubMedGoogle Scholar
  20. 20.
    Chang DM, Lan JL, Lin HY, Luo SF (2002) Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus: a multicenter rrandomized, double-blind, placebo controlled trial. Arthritis Rheum 46:2924–2927CrossRefPubMedGoogle Scholar
  21. 21.
    Contoreggi CS, Blackman MR, Andres R, Muller CD, Lakatta EG, Fleg JL, Harman SM (1990) Plasma estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460–470PubMedGoogle Scholar
  22. 22.
    Davis SR (2002) When to suspect androgen deficiency other than at menopause. Fertil Steril 77 [Suppl 4]:S68–S71Google Scholar
  23. 23.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMedGoogle Scholar
  24. 24.
    Feldman HA, Johannes CB, McKinlay JB, Longcope C (1998) Low dehydroepiandrosterone sulfate and heart disease in middle-aged men : cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol 8:217–228CrossRefPubMedGoogle Scholar
  25. 25.
    Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G (1999) Dehydroepiandrosterone replacement on aging humans. J Clin Endocrinol Metab 84:1527–1533PubMedGoogle Scholar
  26. 26.
    Gebre-Medhin G, Husebye ES, Mallmin H, Helstrom L, Berne C, Karlsson FA, Kampe O (2000) Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison’s disease. Clin Endocrinol 52:775–780CrossRefGoogle Scholar
  27. 27.
    Giraldi A, Persson K, Werkstrom V, Alm P, Wagner G, Andersson KE (2001) Effects of diabetes non neurotransmission in rat vaginal smooth muscle. Int J Impot Res 13:58–66CrossRefPubMedGoogle Scholar
  28. 28.
    Glaser JL, Brind JL, Vogelman JH et coll (1992) Elevated serum dehydroepiandrosterone sulfate levels in practitioners of Transcendental Meditation (MT) and TM-Sidhi programs. J Behav Med 15:327–341PubMedGoogle Scholar
  29. 29.
    Guay AT (2001) Advances in the management of androgen deficiency in women. Med Aspects Hum Sexual 5:32–38Google Scholar
  30. 30.
    Guay AT, Jacobson J (2002) Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEAS) levels in women with decreased libido. J Sex Marital Ther [Suppl] 28:129–142Google Scholar
  31. 31.
    Gurnell EM, Chatterjee VK (2001) Dehydroepiandrosterone replacement therapy. Eur J Endocrinol 145:103–106PubMedGoogle Scholar
  32. 32.
    Hackbert L, Heiman JR (2002) Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. J Womens Health Gender Based Med 11:155–162CrossRefGoogle Scholar
  33. 33.
    Haffner SM, Moss SE, Klein BEK, Klein R (1996) Sex hormones and DHEA-S04 in relation to ischemic heart disease mortality in diabetic subjects: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diab Care 19:1045–1050Google Scholar
  34. 34.
    Hak A E, Witteman J C M, de Jong F H, Geerlings M I, Hofman A, Pols H A P (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 87:3632–3639.PubMedGoogle Scholar
  35. 35.
    Hautanen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H (1994) Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 105:191–200PubMedGoogle Scholar
  36. 36.
    Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, et al (2000) DHEA-S plasma levels and incidence of Alzheimer’s disease. Biol Psychiatr 47:161–163CrossRefGoogle Scholar
  37. 37.
    Hinson JP, Raven PW (1999) DHEA deficiency syndrome: a new term for old age? J Endocrinol 163:1–5PubMedGoogle Scholar
  38. 38.
    Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double-blind trial. J Clin Endocrinol Metab 85:4650–4656PubMedGoogle Scholar
  39. 39.
    Huppert FA, Van Niekerk JK (2002) Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Systematic Reviews, issue 3Google Scholar
  40. 40.
    Johannsson G, Burman P, Engström BE, Nilsson AG, Ottoson M, Jonsson B, Bengtsson BA, Karlsson FA (2002) Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 87:2046–2052PubMedGoogle Scholar
  41. 41.
    Johnson MD, Bebb RA, Sirrs SM (2002) Uses of DHEA in aging and other disease states. Ageing Res Rev 1:29–41CrossRefPubMedGoogle Scholar
  42. 42.
    Kalmijn S, Launer LJ, Stolk RP, De Jong FH, Pols HAP, Hofman A, Breteler MMB, Lamberts SWJ (1998) A prospective study on cortisol, dehydroepiandrosterone sulfate and cognitive function in the elderly. J Clin Endocrinol Metab 83:3487–3492PubMedGoogle Scholar
  43. 43.
    Labbate LA, Fava FS, Pittenger AL, Fabian TJ, Frye RF (1999) DHEA and DHEA-S: a review. J Clin Pharmacol 39:327–48PubMedGoogle Scholar
  44. 44.
    Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82:3498–3505PubMedGoogle Scholar
  45. 45.
    La Croix AZ, Yano K, Reed DM (1992) Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclosis in men. Circulation 86:1529–1535PubMedGoogle Scholar
  46. 46.
    Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, et al (2000) Dehydroepiandrosterone replacement administration : Pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab 85:3208–3217PubMedGoogle Scholar
  47. 47.
    Littman AB, Fava M, Halperin P, et al (1993) Physiologic benefits of a stress reduction program for healthy middle-aged Army officers. J Psychosom Res 37:345–354CrossRefPubMedGoogle Scholar
  48. 48.
    Liu D, Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor couplet to Gαi2,3. Biol Chem 277:21379–21388CrossRefGoogle Scholar
  49. 49.
    Longcope C (1986) Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 15:213–227Google Scholar
  50. 50.
    Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, Myking OL, Kampe O, Husebye ES (2003) Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status ad sexuality in a 9-month, randomized, parallel group trial. J Clin Endocrinol Metab 88:1112–1118CrossRefPubMedGoogle Scholar
  51. 51.
    Mazat L, Lafont S, Berr C, Debuire B, Tessier JF, Dartigues JF, Baulieu EE (2001) Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. PNAS 3:8145–8150CrossRefGoogle Scholar
  52. 52.
    McRaty R, Barrios-Choplin B, Rozman D, et al (1998) The impact of a new emotional self-management program on stress, emotions, heart rate variability, DHEA and cortisol. Integr Physiol Behav Sci 33:151–170PubMedGoogle Scholar
  53. 53.
    Meston CM, Heiman JR (2002) Acute dehydroepiandrosterone effects on sexual arousal in premenopausal women. J Sex Marital Ther 28:53–60CrossRefPubMedGoogle Scholar
  54. 54.
    Min K, Munarriz R, Huang Y, Kim N, Goldstein I, Traish A (2001) Effects of sex steroid hormones on nitric oxide synthase and arginase activity in the vagina (abstract 93). In: Proceedings of the 4th Biennial Congress of the European Society for Sexual and Impotence Research, 30 September–3 October 2001, Rome. Int J Imp Res 13 [Suppl 4]:S34Google Scholar
  55. 55.
    Mitchell LE, Sprecher DL, Borecki IB, Rice LT, Laskarzewski PM, Rao DC (1994) Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 89:89–93PubMedGoogle Scholar
  56. 56.
    Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360–1367PubMedGoogle Scholar
  57. 57.
    Morrisson MF, Katz IR, Parmelee P, Boyce AA, Ten-Have T (1998) Dehydroepiandrosterone sulfate (DHEA-S) and psychiatric and laboratory measures of frailty in a residential care population. Am J Geriatr Psychiatr 6:277–284Google Scholar
  58. 58.
    Morrisson MF, Ten-Have T, Freeman EW, Sammel MD, Grisso JA (2001) DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years. Biol Psychiatry 50:705–711PubMedGoogle Scholar
  59. 59.
    Nippoldt TB, Nair KS (1998) Is there a case for DHEA replacement? In: Bhasin S (ed) The therapeutic role of androgens. Baillieres Clin Endocrinol Metabol 12:507–520Google Scholar
  60. 60.
    Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H (1992) Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75:1002–1004Google Scholar
  61. 61.
    Paolisso G, Ammendola S, Del Buono A, Gambardella M, Riondino M, Tagliamonte MR, Rizzo MR, Carella C, Varrichio M (1997) Serum levels of insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action and cognitive function. J Clin Endocrinol Metab 82:2204–2209PubMedGoogle Scholar
  62. 62.
    Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau M, Marini JF (2003) Effect of 1-year oral administration of dehydroepiandrosterone to 60 to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 163:720–727CrossRefPubMedGoogle Scholar
  63. 63.
    Petri M, Lahita R, Mc Guire J et al (1997) Results of the GL 701 (DHEA) multicenter steroid-sparing SLE study. Arthritis Rheum [Suppl] 40:S327Google Scholar
  64. 64.
    Rabkin JC, Ferrando SJ, Wagner GJ, Rabkin R (2000) DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 25:53–68CrossRefPubMedGoogle Scholar
  65. 65.
    Ravaglia G, Forti P, Maioli F, Boschi F, Bernardi M, Pratelli L, Pizzoferrato A, Gasbarrini G (1996) The relationship of dehydroepiandrosterone sulfate to endocrine-metabolic parameters and functional status in the oldest-old. Results from an italian study on healthy free-living over-90 year olds. J Clin Endocrinol Metab 81:1173–1178PubMedGoogle Scholar
  66. 66.
    Ravaglia G, Forti P, Maioli F, Sacchetti L, Nativio V, Scali CR, MAriani E, Zanardi V, Sefanini A, Macini PL (2002) Dehydroepiandrosterone-sulfate serum levels and common age-related diseases: results from a cross-sectional Italian study of a general elderly population. Exp Gerontol 37:701–712CrossRefPubMedGoogle Scholar
  67. 67.
    Reiter WJ, Pycha A, Schatzl G, Pokorny A, Gruber DM, Huber JC, Marberger M (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53:590–594PubMedGoogle Scholar
  68. 68.
    Reiter WJ, Pycha A, Schatzl G, Klingler H, Märk I, Auterith A, Marberger M (2000) Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology 55:755–758PubMedGoogle Scholar
  69. 69.
    Reiter WJ, Schatzl G, Mark I, Zeiner A, Pycha A, Marberger M (2001) Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29:278–281CrossRefPubMedGoogle Scholar
  70. 70.
    Rigaud AS, Pellerin J (2001) Les effets neuropsychiques de la déhydroépiandrostérone. Ann Med Interne 152 [Suppl 3]:1S43–1S49Google Scholar
  71. 71.
    Rudman D, Shetty KR, Mattson DE (1990) Plasma dehydroepiandrosterone sulfate in nursing home men. J Am Geriatr Soc 38:421–427PubMedGoogle Scholar
  72. 72.
    Sherwin BB, Gelfand MM, Brender W (1985) Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 47:339–351PubMedGoogle Scholar
  73. 73.
    Schlienger JL, Perrin AE, Goichot B (2002) DHEA: célèbre et méconnue. Rev Méd Interne 23:436–446Google Scholar
  74. 74.
    Shifren JL, Braunstein G, Simon J, Casson P, Buster JE, Redmond GP, et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682–688PubMedGoogle Scholar
  75. 75.
    Simpson ER (2002) Aromatization of androgens in women: current concepts and findings. Fertil Steril 77 [Suppl 4]:S6–S10Google Scholar
  76. 76.
    Tissandier O, Peres G, Fiet J, Piette F (2001) Testostérone, dehydroepiandrosterone, insulin-like growth factor 1, and insulin in sedentary and physically trained aged men. Eur J Appl Physiol 85:177–184CrossRefPubMedGoogle Scholar
  77. 77.
    Traish AM, Kim N, Min K, Munarriz R, Goldstein I (2002) Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril 77 [Suppl 4]:S11–S18Google Scholar
  78. 78.
    Trivedi DP, Khaw KT (2001) Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 86:4171–4177PubMedGoogle Scholar
  79. 79.
    Vallée M, Mayo W, Le Moal M (2001) Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Rev 37:301–312CrossRefPubMedGoogle Scholar
  80. 80.
    Van den Beld AW, Bots ML, Janssen JAMLL, Pols HAP, Lamberts SWJ, Grobbee DE (2003) Endogenous hormones and carotid atherosclerosis in men. Am J Epidemiol 157:25–31CrossRefPubMedGoogle Scholar
  81. 81.
    Van Hollenhoven RF, Engelman EG, Mc Guire JL (1995) Dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 38:1826–1831PubMedGoogle Scholar
  82. 82.
    Van Hollenhoven RF, Park JL, Genovese MC, West JP (1999) A double-blind placebo-controlled clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8:181–187PubMedGoogle Scholar
  83. 83.
    Williams MRI, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA (2002) Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and Ers. J Clin Endocrinol Metab 87:176–181PubMedGoogle Scholar
  84. 84.
    Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, Pirke K, Kirschbaum C (1997) Effects of a 2-weeks physiological dehydroepiandrosterone substitution on cognitive performance and well being in healthy elderly women and men. J Clin Endocrinol Metab 82:2263–2267Google Scholar
  85. 85.
    Wolf OT, Neumann E, Hellhammer DH, Kirschbaum C (1998) Effects of dehydroepiandrosterone replacement in elderly men on event related potentials, memory and well-being. J Gerontol 53:M385–390Google Scholar
  86. 86.
    Wolf OT, Kudielka BM, Hellhammer DH, Hellhammer J, Kirschbaum C (1998) Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to laboratory stressor. Psychoneuroendocrinology 23:617–629CrossRefPubMedGoogle Scholar
  87. 87.
    Wolf OT, Kirschbaum C (1999) Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev 30:264–288PubMedGoogle Scholar
  88. 88.
    Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L (1999) Double blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatr 156:646–649PubMedGoogle Scholar
  89. 89.
    Yaffe K, Ettinger B, Pressman A, Seeley D, Whooley M, Schaefer C, et al (1998) Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry 43:694–700CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Centre d’Etude et de Traitement de la Pathologie de l’AppareilReproducteur et de la Psychosomatique (CETPARP)LilleFrance

Personalised recommendations